Indoleamine 2,3‐Dioxygenase 1 as an Adjunctive Histopathological Marker of Cholangitis Activity in Primary Biliary Cholangitis
Hepatology Research · 2026-08-08
DOI: 10.1111/hepr.70256 ↗At a glance
Journal article in Hepatology Research, published online on 2026-08-08. Written by Kaori Yoshimura and 10 co-authors. Institution: Department of Human Pathology, Kanazawa University, Kanazawa, Ishikawa, Japan. 12 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Japan Society for the Promotion of Science, the Intractable Hepato-Biliary Diseases Study Group in Japan.
Abstract (original language)
Aim
To investigate the expression and clinicopathological significance of indoleamine 2,3‐dioxygenase 1 (IDO‐1) in primary biliary cholangitis (PBC), particularly its potential role as an adjunctive histopathological marker for diagnosis in early or atypical cases and as an indicator of disease activity.
Methods
We retrospectively analyzed 83 liver biopsy specimens from patients clinically diagnosed with or suspected of having PBC between 2016 and 2025. IDO‐1 expression in interlobular bile ducts was assessed by immunohistochemistry and correlated with clinical, biochemical, and histological features, including a new histological staging and grading system for PBC. Statistical analyses included univariate and multivariate logistic regression, and a subgroup analysis was performed for patients receiving ursodeoxycholic acid (UDCA).
Results
IDO‐1 was expressed in 64 of 83 cases (77.1%). Our multivariate analysis identified UDCA treatment (OR = 0.105, 95% CI: 0.0138–0.794, p = 0.029) and the cholangitis activity (CA) score (OR = 2.91, 95% CI: 1.18–7.18, p = 0.021) as independent predictors of IDO‐1 expression. IDO‐1 positivity was significantly reduced in UDCA‐treated patients (50.0%) compared with untreated patients (95.9%, p < 0.0001). In the UDCA subgroup, unlike other histological features, IDO‐1 expression remained significantly associated with higher CA scores.
Conclusions
IDO‐1 reflects active cholangitis rather than chronic damage such as fibrosis or bile duct loss. It is a sensitive marker of dynamic immune activity that may serve as an adjunctive histopathological marker.
Subjects
Author keywords
Authors and institutions
- Department of Human Pathology, Kanazawa University, Kanazawa, Ishikawa, Japan.
- Division of Gastroenterology and Hepatology, Kansai Medical University Hospital, Osaka, Japan.
- Department of Gastroenterology, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan.
ORCID profiles: Shinji Shimoda, Quynh Nguyen Thi, Taro Yamashita
Funding
- Japan Society for the Promotion of Science
- the Intractable Hepato-Biliary Diseases Study Group in Japan
Cite
APA
Yoshimura, K., Shimoda, S., Masuda, R., Thi, T. N., Yang, R., Thi, Q. N., Le Thanh, D., Tamano, Y., Sato, Y., Yamashita, T., & Harada, K. (2026). Indoleamine 2,3‐Dioxygenase 1 as an Adjunctive Histopathological Marker of Cholangitis Activity in Primary Biliary Cholangitis. Hepatology Research. https://doi.org/10.1111/hepr.70256
Vancouver
Yoshimura K, Shimoda S, Masuda R, Thi TN, Yang R, Thi QN, et al. Indoleamine 2,3‐Dioxygenase 1 as an Adjunctive Histopathological Marker of Cholangitis Activity in Primary Biliary Cholangitis. Hepatology Research. 2026. doi:10.1111/hepr.70256
BibTeX
@article{Yoshimura2026,
author = {Yoshimura, Kaori and Shimoda, Shinji and Masuda, Ryoka and Thi, Tram Nguyen and Yang, Rui and Thi, Quynh Nguyen and Le Thanh, Dong and Tamano, Yuko and Sato, Yasunori and Yamashita, Taro and Harada, Kenichi},
title = {Indoleamine 2,3‐Dioxygenase 1 as an Adjunctive Histopathological Marker of Cholangitis Activity in Primary Biliary Cholangitis},
journal = {Hepatology Research},
year = {2026},
doi = {10.1111/hepr.70256}
}
EUVIMED